Abstract
Objective To establish a metagenomic profiling method using long-read sequencing for clinical diagnosis of ocular inflammation and detect the etiologic virus of herpetic uveitis.
Design A retrospective, cross-sectional study.
Participants The participants were 44 uveitis patients with a suspected infectious etiology and 22 controls with cataract.
Methods The anterior aqueous humor (10-20 µl) was subjected to DNA purification, followed by whole genome amplification. The Nanopore MinION™ using the Flongle Flow Cell was used to perform rapid long-read sequencing and the phylogenetic composition of the microorganisms in the specimen was evaluated.
Main Outcomes and Measures The detection of the DNA sequence reads of the etiologic virus of herpetic uveitis in the generated FASTQ files from nanopore sequencing and the evaluation of the limits of detection (LOD) of metagenomic analysis compared to multiplex polymerase chain reaction (mPCR) testing for etiologic virus detection of herpetic uveitis.
Results The detection rate of nanopore metagenomic analysis was approximately 59.0% as a result of validation against 22 mPCR-positive cases. The LOD was between 103.6 and 106 copies of virus DNA. The undetectable cases tended to have significantly lower copy numbers by mPCR, suggesting the lower metagenomic analysis sensitivity compared to mPCR. The nine pathogenic microorganisms evaluated by mPCR were also not detected by nanopore in all mPCR-negative cases and controls. The minimum time to obtain analysis results using this method was approximately 190 minutes.
Conclusions and Relevance Our established sequencing protocol from the anterior aqueous humor detected the DNA fragments of etiologic viruses in patients with herpes virus uveitis. Conversely, nanopore metagenomic results contained considerable noise and were found to be less sensitive compared to the conventional mPCR tests for ocular infections.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: KMN had financial support from Nippon Kayaku Co., Ltd. for submitted work; HU has received research grants from Nippon Kayaku Co., Ltd. and honoraria for presentations from Amgen K. K. and Otsuka Pharmaceutical Co.,Ltd. KMN has received honorarium for presentations and support for attending a meeting and travel from AbbVie Inc.; no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This study was supported by a grant from the Japan Society for the Promotion of Science KAKENHI, grant number 20K09765 (Koji M Nishiguchi) and 22K20958 (Ai Fujita Sajiki).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This was a retrospective, observational case series study. We followed the tenets of the Declaration of Helsinki, received ethical approval from the Institutional Review Board of Nagoya University Graduate School of Medicine (2020-0598), and registered the study with the University Hospital Medical Information Network (UMIN000044906). Additionally, we obtained written informed consent from all patients for the testing of the samples. All participants were recruited at Nagoya University Hospital, Tokyo Medical University Hospital, or Yokkaichi Municipal Hospital, and patient clinical information was obtained retrospectively from medical records.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# Co–first author
The following minor corrections have been made to the MS. 1.Correction of the font-style of "and" in the Authors section 2.Correction of the font-style of "was" in the Abstract Methods section 3.Addition of the full name of the abbreviation ONT in the Introduction section 4. Correction of the space between A and B in Figure 2 5. Improved quality of Figure 4.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
